EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy

Mike Wenzel iD, Katrin Burdenski, Nikolaos Tselis, Claus Rödel, Christian Brandts, Marit Ahrens, Jens Koellermann, Markus Graefen, Clara Humke, Carolin Siech, Benedikt Hoeh, Severine Banek und 2 weitere

Strahlentherapie und Onkologie · 2026-02 · 202 (2) · 129-138

DOI: 10.1007/s00066-025-02400-4 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Strahlentherapie und Onkologie, online erschienen am 06.05.2025. Verfasst von Mike Wenzel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Mike.Wenzel@unimedizin-ffm.de. Hauptthemen laut MEDLINE: Prostatectomy, Prostatic Neoplasms, Salvage Therapy. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Frankfurt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Outcomes of adjuvant (aRT) or salvage radiation therapy (sRT) after radical prostatectomy are under investigation regarding cancer-control outcomes.

Methods

Relying on the University Cancer Center database elaborating differences in metastasis-free (MFS), cancer-specific (CSS) and overall survival (OS) of aRT vs. sRT-treated patients between 2014–2024. Sensitivity analyses addressed high-risk patients with pN1 and/or Gleason score 8–10 and/or pT3–4 stage.

Results

Of 1862 patients, 7.1% underwent aRT and 93% were in the sRT group. Median PSA at sRT was 0.33 ng/ml. Patients with aRT harbored significantly worse baseline tumor and pathological characteristics such as PSA level (12.0 vs. 7.6 ng/ml), Gleason score 9–10 (30% vs. 9.8%), D’Amico high risk prostate cancer (97% vs. 56%), as well as pT3–4, pN1 and positive surgical margins rates (all p < 0.001). Similar observations were made for high-risk patients. No differences were observed for aRT vs. sRT with 60-month MFS rates of 85.1% vs. 95.4% (hazard ratio [HR] 0.60, p = 0.18). 60-months CSS-rates of 96.8% vs. 99.1% and 60-month OS-rates of 91.0% vs. 89.1% respectively (all p ≥ 0.15). Neither sensitivity analyses of high-risk patients nor multivariable adjusted Cox regression models revealed significant differences regarding MFS, CSS or OS in aRT vs. SRT comparison (all p ≥ 0.05), despite aRT showing qualitatively better OS results.

Conclusion

Within real-world setting, patients undergoing aRT harbor wore tumor characteristics. However, these differences did not translate into significant differences of mid-term oncological outcomes, relative to sRT patients. Similar observations were made within analyses of high-risk patients with pT3–4 and/or Gleason 8–10 and/or pN1 stage, nevertheless aRT showed slightly higher OS rates within this subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstatectomyProstatic NeoplasmsSalvage TherapyHumansMaleMiddle AgedAgedRadiotherapy, AdjuvantNeoplasm GradingTreatment OutcomeProstate-Specific AntigenSurvival Rate

Stichwörter der Autor:innen

EBRTRARPRadiotherapyRoboticSurvival

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Mike.Wenzel@unimedizin-ffm.de.
  • Department of Urology, Goethe University Hospital Frankfurt, Frankfurt/Main, Germany. Mike.Wenzel@unimedizin-ffm.de.
  • University Cancer Center Frankfurt (UCT), Frankfurt am Main, Germany.
  • Department of Radiation Oncology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Department of Hematology/Oncology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Department of Pathology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.

ORCID-Profile: Mike Wenzel

Förderung

  • Universitätsklinikum Frankfurt

Zitieren

APA

Wenzel, M., Burdenski, K., Tselis, N., Rödel, C., Brandts, C., Ahrens, M., Koellermann, J., Graefen, M., Humke, C., Siech, C., Hoeh, B., Banek, S., Chun, F. K. H., & Mandel, P. (2026). Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy. Strahlentherapie und Onkologie, 202(2), 129-138. https://doi.org/10.1007/s00066-025-02400-4

Vancouver

Wenzel M, Burdenski K, Tselis N, Rödel C, Brandts C, Ahrens M, et al. Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy. Strahlentherapie und Onkologie. 2026;202(2):129-138. doi:10.1007/s00066-025-02400-4

BibTeX
@article{Wenzel2026,
  author = {Wenzel, Mike and Burdenski, Katrin and Tselis, Nikolaos and Rödel, Claus and Brandts, Christian and Ahrens, Marit and Koellermann, Jens and Graefen, Markus and Humke, Clara and Siech, Carolin and Hoeh, Benedikt and Banek, Severine and Chun, Felix K H and Mandel, Philipp},
  title = {Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy},
  journal = {Strahlentherapie und Onkologie},
  year = {2026},
  volume = {202},
  number = {2},
  pages = {129--138},
  doi = {10.1007/s00066-025-02400-4}
}
Kostenlos starten →